CLDN6-CAR-NK Cell Therapy

N/A

Report date: 2024/06/27 20:00:09

Base Information

Drug NameCLDN6-CAR-NK Cell Therapy

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-CLDN6

TargetsClaudin 6

Therapy Area/IndicationsEndometrial NeoplasmsOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

China Registration ClassN/A

Develop Information

Active CompaniesSecond Affiliated Hospital Of Guangzhou Medical University

Inactive CompaniesN/A

Active IndicationsEndometrial NeoplasmsOvarian Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A